Back to today’s briefing

Story perspectives

Singapore Approves Costly Alzheimer's Drugs for 2025 Launch

7/28/2025

43 5

Summary

Story summary

In a groundbreaking move for Alzheimer's treatment, Singapore has greenlit two new monoclonal antibodies, lecanemab and donanemab, set to launch in 2025. While these drugs promise to slow disease progression, they come with hefty price tags—$26,500 and $32,000 per year, respectively—and require careful monitoring due to potential side effects like brain swelling.

1 of 1

Story summary

In a groundbreaking move for Alzheimer's treatment, Singapore has greenlit two new monoclonal antibodies, lecanemab and donanemab, set to launch in 2025. While these drugs promise to slow disease progression, they come with hefty price tags—$26,500 and $32,000 per year, respectively—and require careful monitoring due to potential side effects like brain swelling.